BioPharmSignal logoBioPharmSignal

Biotech News

Vaxcyte Announces Pricing of $550 Million Public Offering

Vaxcyte (PCVX)VaxcyteFinancing

SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of an underwritten public offering of common stock. Vaxcyte is selling 11,000,000 shares of common stock in the offering at a public offering

Related news

PCVXVaxcyte2026-02-02 21:05 EST

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

PCVXVaxcyte2026-01-29 21:07 EST

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

VXRTVaxart2026-04-17 12:30 EST

Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital

View all latest news

Vaxcyte

Carrier-Sparing Vaccine Platform Vaxcyte develops broad-spectrum conjugate vaccines using a platform designed to include more bacterial antigens without overloading the carrier proteins needed to generate immune responses. Adult VAX-31 Program VAX-31 is a 31-valent pneumococcal conjugate vaccine in Phase 3 development for adults. The...

Recent company news

PCVXVaxcyte2026-08-05 20:05 EST

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

PCVXVaxcyte2026-07-08 20:05 EST

Vaxcyte to Participate in Upcoming Investor Conferences

PCVXVaxcyte2026-06-02 20:05 EST

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

PCVXVaxcyte2026-05-06 20:05 EST

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

PCVXVaxcyte2026-04-07 20:05 EST

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

Stock data

Close
58.89 USD
Market cap
6.85B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States